search results for 
Logo

Fresenius group in figures (U.S. GAAP)

€ in millions 2012 2011 2010 2009 2008
1 2011 sales were adjusted by - €161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America. 2 2012 adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG as well as for other one-time costs (€86 million) at Fresenius Medical Care. 3 2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals) 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2012 adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs (€29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG.
2009 - 2011 adjusted for the effects of mark-to-market accounting of the MEB and the CVR.
2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)
5 Including noncontrolling interest 6 Before special items 7Pro-forma Fresenius Kabi USA (formerly APP Pharmaceuticals) and excluding special items 8 Investments in property, plant and equipment, and intangible assets, acquisitions 9 Proposal
Sales and Earnings          
Sales 19,290 16,3611 15,972 14,164 12,336
EBITDA 3,8512 3,237 3,057 2,616 2,2603
EBIT 3,0752 2,563 2,418 2,054 1,7273
Net income (before special items)4 938 770 660 514 450
Depreciation and amortization 776 674 639 562 783
Earnings per share in € (before special items)4 5.42 4.73 4.08 3.18 2.85
Cash flow and Balance sheet          
Operating cash flow 2,438 1,689 1,911 1,553 1,074
Operating cash flow in % of sales 12.6% 10.3% 12.0% 11.0% 8.7%
Total assets 30,664 26,321 23,577 20,882 20,544
Non-current assets 22,551 19,170 17,142 15,519 15,466
Equity5 12,758 10,577 8,844 7,491 6,943
Net debt 10,143 9,164 8,015 7,879 8,417
Net debt/EBITDA 2.6 6 2.8 2.6 3.0 3.67
Equity ratio5 42% 40% 38% 36% 34%
Investments8 4,179 2,395 1,402 931 4,617
Profitability          
EBIT margin 15.9%2 15.7% 15.1% 14.5% 14.0%3
Return on equity after taxes (ROE)4 12.3% 12.9% 13.3% 12.1% 10.5%7
Return on operating assets (ROOA) 11.0%2 10.9% 11.6% 10.5% 9.8%7
Return on invested capital (ROIC) 9.0%2 8.8% 8.9% 8.2% 7.3%7
Dividend per share in € 1.109 0.95 0.86 0.75 0.70
Employees (December 31) 169,324 149,351 137,552 130,510 122,217

€ in millions 2012 2011 2010 2009 2008
1 2011 sales were adjusted by - €161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America. 2 2012 adjusted for one-time costs (€6 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG as well as for other one-time costs (€86 million) at Fresenius Medical Care. 3 2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals) 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2012 adjusted for a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as for one-time costs (€29 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG.
2009 - 2011 adjusted for the effects of mark-to-market accounting of the MEB and the CVR.
2008 adjusted for special items relating to the acquisition of Fresenius Kabi USA (formerly APP Pharmaceuticals)
5 Including noncontrolling interest 6 Before special items 7Pro-forma Fresenius Kabi USA (formerly APP Pharmaceuticals) and excluding special items 8 Investments in property, plant and equipment, and intangible assets, acquisitions 9 Proposal
Sales and Earnings          
Sales 19,290 16,3611 15,972 14,164 12,336
EBITDA 3,8512 3,237 3,057 2,616 2,2603
EBIT 3,0752 2,563 2,418 2,054 1,7273
Net income (before special items)4 938 770 660 514 450
Depreciation and amortization 776 674 639 562 783
Earnings per share in € (before special items)4 5.42 4.73 4.08 3.18 2.85
Cash flow and Balance sheet          
Operating cash flow 2,438 1,689 1,911 1,553 1,074
Operating cash flow in % of sales 12.6% 10.3% 12.0% 11.0% 8.7%
Total assets 30,664 26,321 23,577 20,882 20,544
Non-current assets 22,551 19,170 17,142 15,519 15,466
Equity5 12,758 10,577 8,844 7,491 6,943
Net debt 10,143 9,164 8,015 7,879 8,417
Net debt/EBITDA 2.6 6 2.8 2.6 3.0 3.67
Equity ratio5 42% 40% 38% 36% 34%
Investments8 4,179 2,395 1,402 931 4,617
Profitability          
EBIT margin 15.9%2 15.7% 15.1% 14.5% 14.0%3
Return on equity after taxes (ROE)4 12.3% 12.9% 13.3% 12.1% 10.5%7
Return on operating assets (ROOA) 11.0%2 10.9% 11.6% 10.5% 9.8%7
Return on invested capital (ROIC) 9.0%2 8.8% 8.9% 8.2% 7.3%7
Dividend per share in € 1.109 0.95 0.86 0.75 0.70
Employees (December 31) 169,324 149,351 137,552 130,510 122,217

You will find a 10-year overview on our website: www.fresenius.com under “Investor Relations.”

Continue reading:
Summary of the fiscal year

QUICKFINDER

History

Tools